Almost all individuals with type 1 diabetes (T1D) and approximately 40% of individuals with type 2 diabetes (T2D) experience hypoglycemia at various frequencies depending on the therapies they employ for glycemic control, with exogenous insulin therapy being associated with the highest risk for hypoglycemic exposure (1). This evidence concerns the gene INS and Hypoglycemia.